Disc Medicine

Historical price data

Disc Medicine is a publicly traded, clinical-stage biotech company dedicated to transforming hematology care through a deep understanding of iron biology and erythropoiesis. The company has built a diversified, late-stage pipeline via a capital-efficient strategy of in-licensing and developing assets from major pharmaceutical partners like Roche and AbbVie. Key achievements include the initiation of a Phase 3 trial for bitopertin in EPP/XLP and multiple Phase 2 programs, positioning the company for multiple near-term catalysts. Its strategy focuses on targeting high-need, underserved patient populations with novel mechanisms that modulate hepcidin to either increase or restrict iron availability.

A mechanism-driven approach focused on modulating the hepcidin pathway to either suppress (increase iron availability) or induce (restrict iron) its activity, alongside a separate mechanism modulating heme biosynthesis via GlyT1 inhibition.